Abiomed plans to commence a phased roll-out of the new sheath this quarter. Credit: Abiomed.

Medical technology firm Abiomed has received 510(k) clearance from the US Food and Drug Administration (FDA) for its Impella Low Profile Sheath.

The sheath with modern technological features will cut down procedural steps and enable smooth Impella insertion and removal, resulting in enhanced outcomes.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

While the Low Profile Sheath has the same inner diameter as the 14 French (Fr) sheath used for Impella CP placement, it features a reduced outer diameter by around 2Fr.

The new sheath is the first of its type to be compatible with the Impella single-access technique, which helps eliminate the need for another access site.

The latest clearance will enable Abiomed to commence a phased roll-out of the new sheath this quarter.

Abiomed chief medical officer Chuck Simonton said: “Abiomed’s Low Profile Sheath is a game-changing technological achievement that will further improve patient outcomes by making it even easier for physicians to insert, manage and remove Impella heart pumps.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Impella Low Profile Sheath will ensure ease of use by replacing the peel-away sheath. It will also eliminate the need for a re-access sheath for patients in the intensive care unit.    

The sheath equipped with a hydrophilic-coated long-taper dilator ensures easier delivery into the vasculature. This, in turn, decreases the procedures involved in serial dilation.

Further, Impella can be removed directly from the sheath sans re-wiring, thus easing the process of heart pump removal and vascular closure.

The new solution will also help in reducing bleeding, among other vascular complications.

In September, the FDA granted two approvals related to the clinical research of Abiomed’s Impella heart pumps.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact